Budget 2026-27 launches Biopharma SHAKTI, ISM 2.0, Rare Earth Corridors and container scheme
The Union Budget 2026-27, presented on 1 February 2026, announced Biopharma SHAKTI with ₹10,000 crore over five years, India Semiconductor Mission 2.0, dedicated Rare Earth Corridors in four states and a ₹10,000 crore container manufacturing scheme.
Summary
The Union Budget 2026-27, presented on 1 February 2026, set out a push to scale up manufacturing in seven strategic and frontier sectors. Biopharma SHAKTI (Strategy for Healthcare Advancement through Knowledge, Technology and Innovation) gets ₹10,000 crore over five years, with three new NIPERs, seven upgraded NIPERs and over 1,000 accredited clinical trial sites. India Semiconductor Mission 2.0 will focus on equipment, materials, full-stack Indian IP and supply chains, and the Electronics Components Manufacturing Scheme outlay rises to ₹40,000 crore. Dedicated Rare Earth Corridors will support Odisha, Kerala, Andhra Pradesh and Tamil Nadu. A scheme will help states set up three chemical parks through a challenge route, and a container manufacturing scheme gets over ₹10,000 crore over five years.
Key facts
- Biopharma SHAKTI
- ₹10,000 crore over 5 years; 3 new NIPERs, 7 upgraded; 1,000+ clinical trial sites
- ISM 2.0
- Equipment, materials, full-stack Indian IP, supply chains
- ECMS outlay
- Raised to ₹40,000 crore
- Rare Earth Corridors
- Odisha, Kerala, Andhra Pradesh, Tamil Nadu
- Chemical parks
- 3, via challenge route
- Container manufacturing
- Over ₹10,000 crore over 5 years
Practice MCQs 4 questions
What outlay did the Union Budget 2026-27 announce for Biopharma SHAKTI?
Show answer
Correct answer: D — ₹10,000 crore over 5 years
Which of the following states is NOT among those to be supported by the dedicated Rare Earth Corridors announced in the Union Budget 2026-27?
Show answer
Correct answer: A — Jharkhand
To what amount did the Union Budget 2026-27 raise the outlay of the Electronics Components Manufacturing Scheme?
Show answer
Correct answer: B — ₹40,000 crore
Consider the following about Biopharma SHAKTI, announced in the Union Budget 2026-27: 1. It includes creating three new National Institutes of Pharmaceutical Education and Research and upgrading seven existing ones. 2. It plans a network of over 1,000 accredited India Clinical Trials sites. Which of the above is/are correct?
Show answer
Correct answer: C — Both 1 and 2